CZO.V - Ceapro Inc.

TSXV - TSXV Delayed Price. Currency in CAD
0.55
+0.03 (+5.77%)
At close: 2:31PM EDT
Stock chart is not supported by your current browser
Previous Close0.52
Open0.52
Bid0.53 x 0
Ask0.55 x 0
Day's Range0.52 - 0.55
52 Week Range0.43 - 0.99
Volume2,400
Avg. Volume53,076
Market Cap41.666M
Beta4.04
PE Ratio (TTM)N/A
EPS (TTM)-0.02
Earnings DateNov 21, 2017 - Nov 27, 2017
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • GlobeNewswire11 days ago

    Ceapro Announces Data from Avenanthramides Study Presented at the Nutrition 2018 Meeting

    Tianou Zhang MD, MS, PhD Candidate, at the Laboratory of Physiological Hygiene and Exercise Science, School of Kinesiology at University of Minnesota, presented the abstract titled, “Oat Avenanthramides Protects Against Eccentric Exercise Induced Muscle Inflammation in Human after Downhill Running,” as a part of the Anti-Inflammation Effect of Dietary Bioactive Components session. The objective of the study is to evaluate whether dietary avenanthramides supplementation could attenuate eccentric exercise-induced muscle inflammation.

  • GlobeNewswire19 days ago

    Ceapro Announces Results of 2018 Shareholders’ Meeting

    EDMONTON, Alberta, June 05, 2018-- Ceapro Inc., a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, announced ...

  • GlobeNewswire26 days ago

    Ceapro Inc. Confirms Excellent Bioavailability of its New Water Soluble Chemical Complex Coenzyme Q10-Beta Glucan

    Ceapro Inc.  (CZO.V) (“Ceapro” or the “Company”), a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, today announced positive results from a bioavailability study for its Pressurized Gas eXpanded liquid (PGX) processed new water soluble chemical complex Coenzyme Q10 (CoQ10) beta glucan. While a comprehensive data package will be submitted for publication, top-line results confirmed in a dose response manner excellent bioavailability of Ceapro’s unique CoQ10-BG formulation at concentrations of 3 to 8% CoQ10.

  • GlobeNewswirelast month

    Ceapro Inc. to Provide a Corporate Update at Its Annual General and Special Meeting of Shareholders on May 29, 2018

    Ceapro Inc.  (CZO.V) (“Ceapro” or the “Company”), a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, announced today that Gilles Gagnon, M.Sc., MBA, President and CEO of Ceapro, will provide a corporate update to on-site shareholders on Tuesday, May 29, 2018 at 8:30 a.m. MDT at the Westin Hotel, Edmonton, AB. Mr. Gagnon’s presentation will be followed by the Annual General and Special Meeting of Shareholders to be held at 10:00 a.m. MDT in the Centennial Room of the Westin Hotel. As part of his presentation, Mr. Gagnon will provide a corporate overview and an update on the Company’s de-risked cosmeceuticals business.

  • GlobeNewswirelast month

    Ceapro Inc. Reports 2018 First Quarter Results

    EDMONTON, Alberta, May 17, 2018-- Ceapro Inc., a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, today ...

  • GlobeNewswire2 months ago

    Ceapro Inc. Presents PGX Enabling Technology Case Study at the 12th International Symposium on Supercritical Fluids

    –Ceapro receives issued European Patent for PGX Technology–. –Poster presentation on a new PGX-dried chemical complex gum Arabic/CoQ10–. EDMONTON, Alberta, April 25, 2018-- Ceapro Inc., a growth-stage ...

  • GlobeNewswire2 months ago

    Ceapro Inc. Provides Corporate Update

    Ceapro Inc.  (CZO.V) (“Ceapro” or the “Company”), a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, today provided a summary of 2017 key accomplishments and recent highlights. This base business has enabled us to maintain a solid balance sheet even while initiating the diversification of Ceapro’s business model from a contract manufacturer (CMO) to a biopharmaceutical company that requires significant investment in Research and Development (R&D).

  • GlobeNewswire2 months ago

    Ceapro Inc. Reports 2017 Financial Results

    EDMONTON, Alberta, April 20, 2018-- Ceapro Inc., a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, today ...

  • GlobeNewswire2 months ago

    Ceapro Inc. Announces Important Collaboration with Prestigious Montreal Heart Institute

    Ceapro Inc. (CZO.V), a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, announced today that it has established a long-term formal collaboration with the prestigious Montreal Heart Institute (MHI). While this agreement will consist of multiple projects, it is expected that the first clinical study will assess Ceapro’s beta-glucan as a cholesterol-lowering agent in a multicenter, randomized, double-blind, placebo-controlled clinical trial (pending review and approval of the protocol by Health Canada). “We are honoured to work with the expert team from Montreal Heart Institute, one of the foremost research centers specializing in cardiovascular disease in Canada and beyond.

  • ACCESSWIRE2 months ago

    Today’s Research Reports on Ceapro, Emerald Health Therapeutics, ESSA Pharma and Sernova

    NEW YORK, NY / ACCESSWIRE / April 18, 2018 / Research Driven Investing strives to provide investors with free daily equity research reports analyzing major market events. Take a few minutes to register ...

  • GlobeNewswire2 months ago

    Ceapro Inc. to Present at the 12th International Symposium on Supercritical Fluids

    EDMONTON, Alberta, April 13, 2018-- Ceapro Inc., a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, announced ...

  • GlobeNewswire3 months ago

    Ceapro Announces Acceptance of Abstract for Presentation at the Nutrition 2018 Meeting

    EDMONTON, Alberta, April 03, 2018-- Ceapro Inc., a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, announced ...

  • ACCESSWIRE3 months ago

    Today’s Research Reports on Ceapro, Eyecarrot Innovations, Hamilton Thorne and Hemostemix

    NEW YORK, NY / ACCESSWIRE / March 21, 2018 / Research Driven Investing strives to provide investors with free daily equity research reports analyzing major market events. Take a few minutes to register ...

  • Marketwired5 months ago

    Ceapro Inc. to Consider Judgements in AVAC Ltd. Actions

    Ceapro Inc.   , a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, announced today that Mr. Justice...

  • Marketwired5 months ago

    Ceapro to Present at Noble Capital Markets' 14th Annual Investor Conference

    Ceapro Inc. , a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, announced today that Gilles Gagnon M.Sc.,......

  • Marketwired6 months ago

    Ceapro Announces Grant of Stock Options and Restricted Share Units

    Ceapro Inc. today announced the granting of stock options and restricted share units to employees and officers of the Company. Options to purchase 210,000 common shares were granted pursuant to the...

  • Marketwired7 months ago

    Ceapro Reports 2017 Third Quarter Business Update and Financial Results

    Ceapro Inc. a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, announced today its financial results for......